Article Text
PDFCommentary
AI diagnoses terminal illness care limits: just, or just stingy?
Statistics from Altmetric.com
Footnotes
Contributors LMF solely responsible for this study.
Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
Linked Articles
- Feature article
Read the full text or download the PDF:
Other content recommended for you
- Experiences and perspectives on chimeric antigen receptor (CAR) T-cell therapy among recipients, carers and referrers (RE-TELL): a qualitative study to inform CAR T-cell service design
- Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy
- Costs, challenges and opportunities of decentralised chimeric antigen receptor T-cell production: a literature review and clinical experts’ interviews
- What is CAR T-cell therapy?
- SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
- Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
- Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy
- Threats by artificial intelligence to human health and human existence
- Implications of conscious AI in primary healthcare
- Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2